IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Phone919-998-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.41 million
Profitability
Miscellaneous
Employees58,000
Next Earnings Date5/1/2019 (Confirmed)
OptionableOptionable
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings results on Thursday, February, 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.03. The medical research company had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.40 earnings per share. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
How can I listen to Iqvia's earnings call?
Iqvia will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8009094261.
What guidance has Iqvia issued on next quarter's earnings?
Iqvia issued an update on its FY19 earnings guidance on Thursday, February, 14th. The company provided EPS guidance of $6.20-6.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.28. The company issued revenue guidance of $10.9-11.25 billion, compared to the consensus revenue estimate of $10.91 billion.Iqvia also updated its FY 2019 guidance to $6.20-6.40 EPS.
What price target have analysts set for IQV?
17 brokerages have issued 1 year target prices for Iqvia's shares. Their predictions range from $120.00 to $170.00. On average, they expect Iqvia's stock price to reach $147.20 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for Iqvia.
What is the consensus analysts' recommendation for Iqvia?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 3 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.
Has Iqvia been receiving favorable news coverage?
Media coverage about IQV stock has trended very positive this week, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a coverage optimism score of 3.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Iqvia own?
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
- Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)
Who are Iqvia's major shareholders?
Iqvia's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ardevora Asset Management LLP (0.14%), Strs Ohio (0.14%), Arvest Bank Trust Division (0.11%), Jag Capital Management LLC (0.06%), DNB Asset Management AS (0.06%) and McGuire Investment Group LLC (0.04%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.
Which major investors are selling Iqvia stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Meeder Asset Management Inc., Arvest Bank Trust Division, DNB Asset Management AS, Retirement Systems of Alabama, Oakbrook Investments LLC, Telos Capital Management Inc. and Gateway Investment Advisers LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.
Which major investors are buying Iqvia stock?
IQV stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Columbus Circle Investors, Jag Capital Management LLC, Pennsylvania Trust Co, Pennsylvania Trust Co, Nisa Investment Advisors LLC, Deltec Asset Management LLC and Boston Advisors LLC. View Insider Buying and Selling for Iqvia.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $135.33.
How big of a company is Iqvia?
Iqvia has a market capitalization of $26.77 billion and generates $10.41 million in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.
What is Iqvia's official website?
How can I contact Iqvia?
Iqvia's mailing address is 4820 EMPEROR BLVD., DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (NYSE IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
